Interleukin-6 drives melanoma cell motility through p38α-MAPK-dependent up-regulation of WNT5A expression

Molecular Oncology

Volumn 8, Issue 8, 2014, Pages 1365-1378

  Linnskog, Rickard ^a   Jönsson, Gunilla ^a   Axelsson, Lena ^a   Prasad, Chandra P ^a   Andersson, Tommy ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Cell motility; ERK1 2; Interleukin 6; Melanoma; P38 MAPK; P38 MAPK; STAT3; WNT5A

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SMALL INTERFERING RNA; STAT3 PROTEIN; WNT5A PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STIMULATION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MELANOMA CELL; MELANOMA CELL LINE; MELANOMA METASTASIS; MIGRATION INHIBITION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TARGET CELL; UPREGULATION;

EID: 84911959577     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.05.008     Document Type: Article

References (46)

1. Bergenfelz C., Janols H., Wullt M., Jirstrom K., Bredberg A., Leandersson K. Wnt5a inhibits human monocyte-derived myeloid dendritic cell generation. Scand. J. Immunol. 2013, 78:194-204.
2. Bittner M., Meltzer P., Chen Y., Jiang Y., Seftor E., Hendrix M., Radmacher M., Simon R., Yakhini Z., Ben-Dor A., Sampas N., Dougherty E., Wang E., Marincola F., Gooden C., Lueders J., Glatfelter A., Pollock P., Carpten J., Gillanders E., Leja D., Dietrich K., Beaudry C., Berens M., Alberts D., Sondak V. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000, 406:536-540.
3. Broom O.J., Zhang Y., Oldenborg P.A., Massoumi R., Sjolander A. CD47 regulates collagen I-induced cyclooxygenase-2 expression and intestinal epithelial cell migration. PloS One 2009, 4:e6371.
4. Camilli T.C., Weeraratna A.T. Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progression. Biochem. Pharmacol. 2010, 80:702-711.
5. Da Forno P.D., Pringle J.H., Hutchinson P., Osborn J., Huang Q., Potter L., Hancox R.A., Fletcher A., Saldanha G.S. WNT5A expression increases during melanoma progression and correlates with outcome. Clin. Cancer Res. : An Off. J. Am. Assoc. Cancer Res. 2008, 14:5825-5832.
6. Dissanayake S.K., Olkhanud P.B., O'Connell M.P., Carter A., French A.D., Camilli T.C., Emeche C.D., Hewitt K.J., Rosenthal D.T., Leotlela P.D., Wade M.S., Yang S.W., Brant L., Nickoloff B.J., Messina J.L., Biragyn A., Hoek K.S., Taub D.D., Longo D.L., Sondak V.K., Hewitt S.M., Weeraratna A.T. Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res. 2008, 68:10205-10214.
7. Dissanayake S.K., Wade M., Johnson C.E., O'Connell M.P., Leotlela P.D., French A.D., Shah K.V., Hewitt K.J., Rosenthal D.T., Indig F.E., Jiang Y., Nickoloff B.J., Taub D.D., Trent J.M., Moon R.T., Bittner M., Weeraratna A.T. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J.Biol. Chem. 2007, 282:17259-17271.
8. Eulenfeld R., Dittrich A., Khouri C., Muller P.J., Mutze B., Wolf A., Schaper F. Interleukin-6 signalling: more than Jaks and STATs. Eur. J. Cell Biol. 2012, 91:486-495.
9. Fidler I.J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 1978, 38:2651-2660.
10. Fujio Y., Matsuda T., Oshima Y., Maeda M., Mohri T., Ito T., Takatani T., Hirata M., Nakaoka Y., Kimura R., Kishimoto T., Azuma J. Signals through gp130 upregulate Wnt5a and contribute to cell adhesion in cardiac myocytes. FEBS Lett. 2004, 573:202-206.
11. Grossmann A.H., Yoo J.H., Clancy J., Sorensen L.K., Sedgwick A., Tong Z., Ostanin K., Rogers A., Grossmann K.F., Tripp S.R., Thomas K.R., D'Souza-Schorey C., Odelberg S.J., Li D.Y. The small GTPase ARF6 stimulates beta-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis. Sci. Signaling 2013, 6:ra14.
12. Hanafusa H., Ninomiya-Tsuji J., Masuyama N., Nishita M., Fujisawa J., Shibuya H., Matsumoto K., Nishida E. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J.Biol. Chem. 1999, 274:27161-27167.
13. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 1998, 334(Pt 2):297-314.
14. Hoejberg L., Bastholt L., Johansen J.S., Christensen I.J., Gehl J., Schmidt H. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res. 2012, 22:287-293.
15. Jenei V., Sherwood V., Howlin J., Linnskog R., Safholm A., Axelsson L., Andersson T. A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:19473-19478.
16. Johnston P.A., Grandis J.R. STAT3 signaling: anticancer strategies and challenges. Mol. Interventions 2011, 11:18-26.
17. Katoh M., Katoh M. Comparative genomics on Wnt5a and Wnt5b genes. Int. J. Mol. Med. 2005, 15:749-753.
18. Katoh M., Katoh M. STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review). Int. J. Mol. Med. 2007, 19:273-278.
19. Katula K.S., Joyner-Powell N.B., Hsu C.C., Kuk A. Differential regulation of the mouse and human Wnt5a alternative promoters A and B. DNA Cell Biol. 2012, 31:1585-1597.
20. Kikuchi A., Yamamoto H., Sato A., Matsumoto S. Wnt5a: its signalling, functions and implication in diseases. Acta Physiol. 2012, 204:17-33.
21. Kiuchi N., Nakajima K., Ichiba M., Fukada T., Narimatsu M., Mizuno K., Hibi M., Hirano T. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J.Exp. Med. 1999, 189:63-73.
22. Kurayoshi M., Yamamoto H., Izumi S., Kikuchi A. Post-translational palmitoylation and glycosylation of Wnt-5a are necessary for its signalling. Biochem. J. 2007, 402:515-523.
23. Kushiro K., Chu R.A., Verma A., Nunez N.P. Adipocytes promote B16BL6 melanoma cell invasion and the epithelial-to-mesenchymal transition. Cancer Microenviron. : Off. J. Int. Cancer Microenviron. Soc. 2012, 5:73-82.
24. Li B., Shi Y., Shu J., Gao J., Wu P., Tang S.J. Wingless-type mammary tumor virus integration site family, member 5A (Wnt5a) regulates human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein 120 (gp120)-induced expression of pro-inflammatory cytokines via the Ca2+/calmodulin-dependent protein kinase II (CaMKII) and c-Jun N-terminal kinase (JNK) signaling pathways. J.Biol. Chem. 2013, 288:13610-13619.
25. Lopez-Bergami P. The role of mitogen- and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res. 2011, 24:902-921.
26. Ma L., Wang H.Y. Mitogen-activated protein kinase p38 regulates the Wnt/cyclic GMP/Ca2+ non-canonical pathway. J.Biol. Chem. 2007, 282:28980-28990.
27. Moretti S., Pinzi C., Spallanzani A., Berti E., Chiarugi A., Mazzoli S., Fabiani M., Vallecchi C., Herlyn M. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int. J. of Cancer J. international du cancer 1999, 84:160-168.
28. O'Connell M.P., Fiori J.L., Xu M., Carter A.D., Frank B.P., Camilli T.C., French A.D., Dissanayake S.K., Indig F.E., Bernier M., Taub D.D., Hewitt S.M., Weeraratna A.T. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 2010, 29:34-44.
29. O'Connell M.P., Marchbank K., Webster M.R., Valiga A.A., Kaur A., Vultur A., Li L., Herlyn M., Villanueva J., Liu Q., Yin X., Widura S., Nelson J., Ruiz N., Camilli T.C., Indig F.E., Flaherty K.T., Wargo J.A., Frederick D.T., Cooper Z.A., Nair S., Amaravadi R.K., Schuchter L.M., Karakousis G.C., Xu W., Xu X., Weeraratna A.T. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discovery 2013, 3:1378-1393.
30. O'Connell M.P., Weeraratna A.T. Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell Melanoma Res. 2009, 22:724-739.
31. Prasad C.P., Chaurasiya S.K., Axelsson L., Andersson T. WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells. Mol. Oncol. 2013, 7:870-883.
32. Sanz-Moreno V., Gaggioli C., Yeo M., Albrengues J., Wallberg F., Viros A., Hooper S., Mitter R., Feral C.C., Cook M., Larkin J., Marais R., Meneguzzi G., Sahai E., Marshall C.J. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 2011, 20:229-245.
33. Säfholm A., Leandersson K., Dejmek J., Nielsen C.K., Villoutreix B.O., Andersson T. A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. J. Biol. Chem. 2006, 281:2740-2749.
34. Sherwood V., Chaurasiya S.K., Ekstrom E.J., Guilmain W., Liu Q., Koeck T., Brown K., Hansson K., Agnarsdottir M., Bergqvist M., Jirstrom K., Ponten F., James P., Andersson T. WNT5A-mediated beta-catenin-independent signalling is a novel regulator of cancer cell metabolism. Carcinogenesis 2014, 35:784-794.
35. Siddiquee K., Zhang S., Guida W.C., Blaskovich M.A., Greedy B., Lawrence H.R., Yip M.L., Jove R., McLaughlin M.M., Lawrence N.J., Sebti S.M., Turkson J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl Acad. of Sci. U.S.A. 2007, 104:7391-7396.
36. Tarhini A.A., Agarwala S.S. Cutaneous melanoma: available therapy for metastatic disease. Dermatol. Ther. 2006, 19:19-25.
37. Wang X.H., Liu B.R., Qu B., Xing H., Gao S.L., Yin J.M., Wang X.F., Cheng Y.Q. Silencing STAT3 may inhibit cell growth through regulating signaling pathway, telomerase, cell cycle, apoptosis and angiogenesis in hepatocellular carcinoma: potential uses for gene therapy. Neoplasma 2011, 58:158-171.
38. Webster M.R., Weeraratna A.T. A Wnt-er migration: the confusing role of beta-catenin in melanoma metastasis. Sci. Signaling 2013, 6:pe11.
39. Weeraratna A.T., Jiang Y., Hostetter G., Rosenblatt K., Duray P., Bittner M., Trent J.M. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002, 1:279-288.
40. Witze E.S., Connacher M.K., Houel S., Schwartz M.P., Morphew M.K., Reid L., Sacks D.B., Anseth K.S., Ahn N.G. Wnt5a directs polarized calcium gradients by recruiting cortical endoplasmic reticulum to the cell trailing edge. Dev. Cell 2013, 26:645-657.
41. Xie T.X., Huang F.J., Aldape K.D., Kang S.H., Liu M., Gershenwald J.E., Xie K., Sawaya R., Huang S. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006, 66:3188-3196.
42. Ying J., Li H., Yu J., Ng K.M., Poon F.F., Wong S.C., Chan A.T., Sung J.J., Tao Q. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin. Cancer Res. : An Off. J. Am. Assoc.Cancer Res. 2008, 14:55-61.
43. Yu L., Hebert M.C., Zhang Y.E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 2002, 21:3749-3759.
44. Zauberman A., Zipori D., Krupsky M., Ben-Levy R. Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3. Oncogene 1999, 18:3886-3893.
45. Zhang X., Zhang J., Wei H., Tian Z. STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes. Oncol. Rep. 2007, 17:1377-1382.
46. Zhong Z., Wen Z., Darnell J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95-98.